Advertisement
Advertisement
KPRX
Kiora Pharmaceuticals, Inc. Common Stock
1.44
USDSponsored
-0.06
-4.00%
Nov 06, 15:59 UTC -5
Closed
Pre-Market
1.46
+0.02
+1.25%
Kiora Pharmaceuticals, Inc. Common Stock (KPRX) Earnings
KPRX Earnings Reports
Positive Surprise Ratio
KPRX beat 26 of 41 last estimates.
63%
Next Report
Date of Next Report
Mar 23, 2027
Estimate for Q4 26 (Revenue/ EPS)
--
/-$0.42
Implied change from Q3 26 (Revenue/ EPS)
--
/--
Implied change from Q4 25 (Revenue/ EPS)
--
/-73.58%
Kiora Pharmaceuticals, Inc. Common Stock earnings per share and revenue
On Nov 06, 2026, KPRX reported earnings of -- USD per share (EPS) for Q3 26, -- the estimate of -0.38 USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference.
Looking ahead to Q4 26, -- analysts forecast an EPS of -0.42 USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Aldeyra Therapeutics, Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.06
Surprise
+37.43%
Lipocine Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.36
Actual
-$0.08
Surprise
+77.91%
Ernexa Therapeutics Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$3.91
Actual
-$1.89
Surprise
+51.75%
ZOETIS INC.
Report Date
Nov 05, 2026 For Q3 26
Estimate
$1.52
Actual
$1.75
Surprise
+14.64%
Dyne Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.92
Actual
-$1.06
Surprise
-15.57%
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.38
Actual
-$0.38
Surprise
+1.04%
Cronos Group Inc. Common Share
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.03
Actual
$0.04
Surprise
+17.65%
Aclaris Therapeutics, Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.12
Surprise
+28.49%
Protara Therapeutics, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.35
Surprise
+6.17%
Minerva Neurosciences, Inc
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.12
Actual
$1.94
Surprise
+1,629.97%
FAQ
What were Kiora Pharmaceuticals, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Kiora Pharmaceuticals, Inc. Common Stock reported EPS of --, missing estimates by --, and revenue of --, 0% as expectations.
How did the market react to Kiora Pharmaceuticals, Inc. Common Stock's Q3 2026 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Kiora Pharmaceuticals, Inc. Common Stock expected to report next?
The next earning report is scheduled for Mar 23, 2027.
What are the forecasts for Kiora Pharmaceuticals, Inc. Common Stock's next earnings report?
Based on --
analysts, Kiora Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.42 and revenue of -- for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.